Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
28
XCUR Quote, Financials, Valuation and Earnings
Last price:
$5.57
Seasonality move
:
-14.66%
Day range:
$5.32 - $5.64
52-week range:
$3.10 - $15.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.99x
Volume:
42.1K
Avg. volume:
1.4M
1-year change:
-60.35%
Market cap:
$34.5M
Revenue:
$500K
EPS (TTM):
-$1.51
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Exicure, Inc. has 84.5% upside to fair value with a price target of -- per share.
XCUR vs. S&P 500
-
Over the past 5 trading days, Exicure, Inc. has underperformed the S&P 500 by -6.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Exicure, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Exicure, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Exicure, Inc. reported revenues of --.
Earnings Growth
-
Exicure, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Exicure, Inc. reported earnings per share of -$0.39.
Enterprise value:
30.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$515K
Return On Assets:
-57.41%
Net Income Margin (TTM):
--
Return On Equity:
-130.03%
Return On Invested Capital:
-94.15%
Operating Margin:
-167.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $21.8M | $500K | -- | -- | -- | |
| Gross Profit | $20.1M | -$309K | -$515K | -$208K | -$67K | |
| Operating Income | $6M | -$5M | -$9.3M | -$1.4M | -$2.4M | |
| EBITDA | $7.7M | -$4.2M | -$8.8M | -$1.2M | -$2.3M | |
| Diluted EPS | $8.56 | -$2.26 | -$1.51 | -$0.57 | -$0.39 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $64.1M | $17.2M | $3.1M | $2.6M | $5.4M | |
| Total Assets | $77.9M | $28.9M | $13M | $10.6M | $15.3M | |
| Current Liabilities | $22M | $25.7M | $2.2M | $3.7M | $2.8M | |
| Total Liabilities | $63.9M | $32.6M | $8.5M | $9.1M | $8.3M | |
| Total Equity | $14M | -$3.7M | $4.5M | $1.5M | $6.9M | |
| Total Debt | $24.8M | $6.9M | $6.2M | $5.4M | $26K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.8M | -$2.9M | -$8.3M | -$449K | -$3.5M | |
| Cash From Investing | -$1.6M | $711K | -$2.3M | -- | $108K | |
| Cash From Financing | $3.7M | $999K | $14M | -- | -- | |
| Free Cash Flow | -$16.8M | -$2.9M | -$8.5M | -$449K | -$3.4M | |
XCUR
Sector
Market Cap
$34.5M
$28.1M
Price % of 52-Week High
34.07%
50%
Dividend Yield
0%
0%
Shareholder Yield
-48.38%
-1.54%
1-Year Price Total Return
-60.35%
-17.67%
Beta (5-Year)
4.062
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.75
200-day SMA
Sell
Level
$7.31
Bollinger Bands (100)
Buy
Level
3.93 - 5.95
Chaikin Money Flow
Sell
Level
-331.1K
20-day SMA
Sell
Level
$5.86
Relative Strength Index (RSI14)
Sell
Level
49.35
ADX Line
Sell
Level
19.95
Williams %R
Buy
Level
-84.2749
50-day SMA
Buy
Level
$4.91
MACD (12, 26)
Buy
Level
1.54
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-373.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.7682)
Sell
CA Score
(Annual)
Level (-2.7322)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.7562)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, XCUR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XCUR average analyst price target in the past 3 months is --.
-
Where Will Exicure, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Exicure, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Exicure, Inc.?
Analysts are divided on their view about Exicure, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Exicure, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Exicure, Inc.'s Price Target?
The price target for Exicure, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XCUR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Exicure, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of XCUR?
You can purchase shares of Exicure, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Exicure, Inc. shares.
-
What Is The Exicure, Inc. Share Price Today?
Exicure, Inc. was last trading at $5.57 per share. This represents the most recent stock quote for Exicure, Inc.. Yesterday, Exicure, Inc. closed at $5.42 per share.
-
How To Buy Exicure, Inc. Stock Online?
In order to purchase Exicure, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XCUR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XCUR
Sector
P/E ratio
--
23.88x
PEG ratio
--
-0.01x
P/B ratio
4.99x
1.82x
Price / LTM sales
--
1.59x
Growth Metrics
XCUR
Sector
Revenue growth
--
4.73%
Earnings growth
32.89%
11.11%
Revenue (5-year growth)
-17.34%
6.46%
Earnings forecast
--
-$0.18
Profitability
XCUR
Sector
Profitability FY 2024
-$324K
$3.6M
Return on invested capital
-94.15%
-31.77%
Return on assets
-57.41%
-28.18%
Return on equity
-130.03%
-37.47%
Earnings Date
Last Earnings Date
Jan
2
Next Earnings Date
Jan
2
Estimated Next Earnings Date
Apr
3
Balance Sheet
XCUR
Sector
Total cash
$4.4M
$26.3M
Short term investments
--
$26M
Total assets
$15.1M
$76.9M
Long term debt
$26K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.12% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.13% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 7.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
